Q3 2025 Performance - Consumables revenue reached $285 million in Q3 2025, representing an 8% year-over-year growth[8] - Systems revenue increased to $174 million in Q3 2025, a 9% year-over-year increase[8] - Vital Care revenue declined significantly to $74 million in Q3 2025, a 52% year-over-year decrease[8] - Total ICU Medical revenue was $533 million in Q3 2025, reflecting an 8% year-over-year decrease[8] 2025 Guidance Update (Post JV Transaction) - Adjusted EBITDA is projected to be between $395 million and $405 million[9] - Adjusted EPS is expected to be between $735 and $765[9] - Consolidated revenue is expected to have a ~ (6%) FXN impact, with low to mid single digits organic growth[9] - Vital Care is expected to have a ~ (35%) FXN impact, with flat organic growth[9] - Net interest expenses are projected to be around $19 million in Q4[9] - Capital expenditures are estimated to be between $85 million and $95 million[9]

Core Insights - ICU Medical, Inc. reported a revenue of $537.0 million for Q3 2025, a decrease from $589.1 million in Q3 2024, indicating a year-over-year decline of approximately 8.8% [2] - The company achieved a GAAP gross profit of $200.9 million with a gross margin of 37%, an improvement from 35% in the same period last year [2] - The net loss for Q3 2025 was $(3.4) million, significantly reduced from a net loss of $(33.0) million in Q3 2024, translating to a loss per diluted share of $(0.14) compared to $(1.35) [2][12] - Adjusted diluted earnings per share rose to $2.03 from $1.59 year-over-year, while adjusted EBITDA increased to $105.9 million from $94.8 million [2][3] Financial Performance - Revenue breakdown for Q3 2025 by product line showed: - Consumables: $285.1 million, up from $264.9 million (increase of $20.2 million) - Infusion Systems: $173.9 million, up from $159.8 million (increase of $14.1 million) - Vital Care: $78.0 million, down from $164.5 million (decrease of $86.5 million) [3] - For the nine months ended September 30, 2025, total revenue was $1,690.5 million, down from $1,752.2 million in the same period of 2024 [3] Fiscal Year Guidance - The company updated its fiscal year 2025 guidance for GAAP net loss to a range of $(8) million to $0 million, an improvement from the previous range of $(43) million to $(35) million [4] - Adjusted EBITDA guidance for the full year was revised to a range of $395 million to $405 million, up from $380 million to $390 million [4] - Diluted earnings per share guidance was also increased to a range of $7.35 to $7.65 from $6.85 to $7.15 [4] Conference Call - A conference call to discuss the third quarter 2025 financial results was scheduled for today at 4:30 p.m. ET, accessible via phone and webcast [5] Company Overview - ICU Medical is a global leader in infusion systems and high-value critical care products, focusing on quality, innovation, and value for clinical customers worldwide [6]

Q1 2025 Performance - ICU Medical's total revenue for Q1 2025 was $599 million[7] - Consumables revenue in Q1 2025 reached $266 million, with a year-over-year growth of 9% (10% FXN)[7] - Systems revenue for Q1 2025 was $166 million, showing a year-over-year growth of 6% (8% FXN)[7] - Vital Care revenue in Q1 2025 amounted to $167 million, reflecting a year-over-year growth of 10% (11% FXN)[7] 2025 Guidance (Post JV Transaction) - Adjusted EBITDA is projected to be between $380 million and $405 million[8] - Adjusted EPS is expected to be in the range of $655 to $725[8] - Vital Care revenue is expected to decline by approximately 35% FXN, but remain flat organically[8] - Capital Expenditures are estimated to be between $75 million and $95 million[8] 2025 Guidance Assumptions - Gross Margin percentage is projected to be between 39% and 40%[8] - SG&A and R&D expenses are expected to be approximately 26% of revenue[8] - Net interest expense is estimated to be around $87 million[8]

Core Viewpoint - ICU Medical, Inc. reported a revenue increase of 6.7% year-over-year for Q1 2025, reaching $604.7 million, while also showing improvements in gross profit and adjusted earnings per share [2][3][4]. Financial Performance - Revenue for Q1 2025 was $604.7 million, compared to $566.7 million in Q1 2024, marking a $38 million increase [2][4]. - GAAP gross profit for Q1 2025 was $210.1 million, up from $185.2 million in Q1 2024, resulting in a gross margin of 35% compared to 33% in the prior year [2][4]. - The GAAP net loss for Q1 2025 was $(15.5) million, or $(0.63) per diluted share, an improvement from a net loss of $(39.5) million, or $(1.63) per diluted share, in Q1 2024 [2][4][13]. - Adjusted diluted earnings per share for Q1 2025 was $1.72, compared to $0.96 in Q1 2024 [2][4]. Revenue Breakdown - Revenue by product line for Q1 2025 included: - Consumables: $266.2 million, up from $244.1 million in Q1 2024, a change of $22.1 million [4]. - Infusion Systems: $166.3 million, an increase of $9 million from $157.3 million in Q1 2024 [4]. - Vital Care: $172.2 million, up by $6.9 million from $165.3 million in Q1 2024 [4]. Cash Flow and Liquidity - Net cash provided by operating activities for Q1 2025 was $51.3 million, compared to $45.8 million in Q1 2024 [36]. - Free cash flow for Q1 2025 was $36.7 million, an increase from $30.4 million in Q1 2024 [36]. Conference Call - The company hosted a conference call to discuss its Q1 2025 financial results, providing insights into its performance and future expectations [6]. Company Overview - ICU Medical is a global leader in infusion systems and high-value critical care products, focusing on quality, innovation, and value for clinical customers worldwide [7].